ALK and non-small cell lung carcinoma: It also has inhibitory activity against several acquired ALK mutations but questionable activity against G1202R. US FDA granted accelerated approval to brigatinib for treatment of individuals with advanced ALK-altered NSCLC that had progressed or were intolerant to crizotinib; approval was based on results of phase II ALTA124 and in first-line setting based on results from Phase III ALTA-1L trial121.